Company Xenetic Biosciences Inc Nasdaq
Equities
US9840152063
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapeutics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +48.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +48.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 03/17/03 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/14/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14/17/14 |
Director/Board Member | 56 | 01/04/01 | |
Roger Kornberg
BRD | Director/Board Member | 77 | 29/16/29 |
Director/Board Member | 72 | 23/14/23 | |
Director/Board Member | 54 | 19/19/19 | |
Director/Board Member | 68 | 14/17/14 | |
Director/Board Member | 55 | 25/19/25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,804,394 | 0 | 0 | 80.81 % |
Stock B | 1 | 1,543,385 | 1,247,242 ( 80.81 %) | 2,701 ( 0.1750 %) | |
Stock C | 0 | 970,000 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+8.29% | 11TCr | |
+10.21% | 11TCr | |
+0.41% | 2.23TCr | |
-11.90% | 2.22TCr | |
-5.99% | 1.94TCr | |
-37.36% | 1.79TCr | |
-5.17% | 1.72TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |